<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600249</url>
  </required_header>
  <id_info>
    <org_study_id>TENEO</org_study_id>
    <nct_id>NCT00600249</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy of a Neoadjuvant Combination: &quot;Chemotherapy-targeted Therapy&quot; in Breast Cancer.</brief_title>
  <official_title>Phase II Pilot Study Evaluating the Neoadjuvant Combination &quot;Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and &quot;Triple Negative&quot; Breast Cancer Patients. TENEO Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Jean Perrin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pathological response rate in operable breast
      cancer patients treated by neoadjuvant combination &quot;Taxotere-Erbitux&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response assessment of Taxotere-Erbitux combination</measure>
    <time_frame>After 18 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical, mammographic and ultrasound response Breast cancer conservation rate Overall and disease free survival Safety to treatments</measure>
    <time_frame>After 18 weeks of treatment, at surgery and at five years (survival)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks</description>
    <other_name>Current sponsor code: EMD271786</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>100mg/m2 every 21 days 6 cycles of 21 days</description>
    <other_name>CAS: 148408-66-6</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  § Age &gt; or equal to 18 years.§

          -  Performance status inferior or equal to 1 (WHO criteria)

          -  Histologically proven breast cancer, non metastatic, with clinical tumor diameter &gt; or
             equal to 2 cm.

          -  HR negative and HER 2 negative.

          -  Clinical stage II and IIIa.

          -  Non prior treated patients either by surgery, radiotherapy, hormonotherapy or
             chemotherapy.§

          -  Adequate hematological, renal and hepatic functions : neutrophils &gt; 2.109 /L,
             platelets &gt; 100.109 /L, Hb &gt; 10 g/dL, normal bilirubin, ASAT and ALAT inferior or
             equal to 2,5 ULN (upper normal limit), alkaline phosphatases £ 2,5 ULN, creatinine &lt;
             140 µmol/L or creatinine clearance &gt; 60 mL/min.§

          -  Written informed consent§

          -  Affiliation with social security system (or profit being of such a mode) according to
             terms' of the law of August 9, 2004.

        Exclusion Criteria:

          -  Male patient.

          -  Pregnant or lactating women or childbearing potential with no efficacy contraception.

          -  Other breast cancer form and particularly inflammatory form and/or negliged (T4b or
             T4d).§

          -  Non measurable tumor.

          -  Prior surgery or primary axillary dissection.

          -  Prior treatment for this new breast cancer.

          -  Under guardianship patient

          -  Patient with antecedent of second cancer, excepted in situ uterine carcinoma or
             baso-cellular cutaneous cancer considered as definitively cured.

          -  Patient with an associated pathology considered incompatible with the study.§ Cardiac,
             renal, medullar, respiratory or hepatic insufficiency.

          -  Significant neurological or psychiatric troubles.§ Symptomatic or evolutive troubles
             in CNS or metastasis.

          -  Peripheral neuropathy &gt; grade 2 NCI-CTC (version 3.0)

          -  Previous allergy with polysorbate 80.

          -  Concomitant treatment with a drug tested in a clinical trial, participation to another
             clinical study, for the last thirty days or prior chemotherapy.

          -  Patients non stable for the following 6 months or leaving at a great distance of the
             participating center.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Chollet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Perrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Montluçon</city>
        <zip>03113</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la LOIRE</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Georges Pianta</name>
      <address>
        <city>Thonon les Bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer.</keyword>
  <keyword>Triple negative.</keyword>
  <keyword>Neoadjuvant chemotherapy.</keyword>
  <keyword>Targeted therapy.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

